DGAP-News: Astex Pharmaceuticals to Present at EORTC-NCI-AACR
(firmenpresse) - Astex Pharmaceuticals, Inc.
31.10.2012 11:00
---------------------------------------------------------------------------
DUBLIN, Calif., 2012-10-31 11:00 CET (GLOBE NEWSWIRE) --
Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated
to the discovery and development of novel small molecule therapeutics, today
announced the acceptance of three abstracts for presentation at the
EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. Poster
presentations will occur Nov 7 - 9 in Dublin, Ireland.
XIAP Abstract #85, Poster Board #052
Poster Presentation: Wednesday, Nov 7, 2012 12:00 - 2:15 pm
GMT
Characterization of a potent XIAP and cIAP1 dual antagonist in models of
melanoma and leukemia
AT13387 Abstract #293, Poster Board #043
Poster Presentation: Thursday, Nov 8, 2012 12:00 - 2:15 pm
GMT
Activity of the HSP90 inhibitor, AT13387, in ALK-driven tumor models
SGI-110 Abstract #465, Poster Board #036
Poster Presentation Friday, Nov 9, 2012 8:30 - 10:30 am
GMT
SGI-110, a novel second generation DNA hypomethylating agent, enhances sorafenib
activity and alters methylation signature of HCC cell lines
Select posters will be made available for viewing on the company's website
http://astx.com/pipeline/publications/ following the public presentation.
About Astex Pharmaceuticals
Astex Pharmaceuticals is dedicated to the discovery and development of novel
small molecule therapeutics with a focus on oncology. The Company is developing
a proprietary pipeline of novel therapies and is creating de-risked products
for partnership with leading pharmaceutical companies. Astex Pharmaceuticals
developed DACOGEN(r) (decitabine) for Injection and receives significant
royalties on global sales.
For more information about Astex Pharmaceuticals, Inc., please visit
http://www.astx.com.
The Astex Pharmaceuticals, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=12273
CONTACT: Timothy L. Enns
Astex Pharmaceuticals, Inc.
Senior Vice President
Corporate Communications&Marketing
Tel: +1 (925) 560-2810
E-mail: tim.enns(at)astx.com
Alan Roemer
The Trout Group
Managing Director
Tel: +1 (646) 378-2945
E-mail: aroemer(at)troutgroup.com
Susanna Chau
Astex Pharmaceuticals, Inc.
Manager
Investor Relations
Tel: +1 (925) 560-2845
E-mail: susanna.chau(at)astx.com
Kari Watson
MacDougall Biomedical Communications
Senior Vice President
Tel: +1 (781) 235-3060
E-mail: kwatson(at)macbiocom.com
News Source: NASDAQ OMX
31.10.2012 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Astex Pharmaceuticals, Inc.
United States
Phone:
Fax:
E-mail:
Internet:
ISIN: US04624B1035
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 31.10.2012 - 11:00 Uhr
Sprache: Deutsch
News-ID 197909
Anzahl Zeichen: 4743
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 278 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Astex Pharmaceuticals to Present at EORTC-NCI-AACR"
steht unter der journalistisch-redaktionellen Verantwortung von
Astex Pharmaceuticals, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
